Abstract: Objective To assess the efficacy of biphasic insulin aspart 50 in the management of patients with hepatogenic diabetes（HD）. Methods One hundred and seventeen patients with HD were recruited in this study. They were randomoly divided into glargine and acarbose group （n=58） and insulin aspart 50-treated group （n=59）. The dose of insulin was adjusted according to fasting blood glucose （FBG）,2 h postprandial blood glucose（2 h PBG）. FBG,2 hPBG and glycosylated hemoglobin （HbAlc） were monitored for 12 weeks. Blood HbAlc,blood glucose levels,glycemic control time and incidence of hypoglycemia were compared between the two groups. Results At the end of 12 weeks,FBG level in insulin aspart 50-treated group was（5.97±1.26）mmol/L,not significantly different as compared to （5.54±1.48） mmol/L in glargine-treated group （P>0.05）,while the PBG level was（7.45±2.56）mmol/L,significantly lower than（8.95±2.44）mmol/L in glargine group （P<0.05）;meanwhile, the HbA1c level was（6.81±0.23）%,significant lower than （7.56±0.31）% in glargine group （P<0.05）;the dose of insulin was（37.2±7.0）U·d-1 in insulin aspart 50 group,not significantly different as compared to（35.1±6.8）U·d-1 in glargine group（P>0.05）;the glycemic control time was（14.2±2.8）d in insulin aspart 50 injection group,not significantly different as compared to（14.5±3.2）d in glargine group（P>0.05）;the incidence of hypoglycemia was 3.5% in insulin aspart injection group,not significantly different as compared to 5.1% in glargine group（P>0.05）. Conclusion Biphasin insulin aspart 50 therapy is effective and safe for patients with HD.

Key words: Hepatogenous diabetes, Biphasic insulin aspart 50, Therapy